FI67371C - Foerfarande foer framstaellning av nya farmakologiskt aktiva fenylazacykloalkaner - Google Patents

Foerfarande foer framstaellning av nya farmakologiskt aktiva fenylazacykloalkaner Download PDF

Info

Publication number
FI67371C
FI67371C FI814080A FI814080A FI67371C FI 67371 C FI67371 C FI 67371C FI 814080 A FI814080 A FI 814080A FI 814080 A FI814080 A FI 814080A FI 67371 C FI67371 C FI 67371C
Authority
FI
Finland
Prior art keywords
compound
group
formula
carbon atoms
hcl
Prior art date
Application number
FI814080A
Other languages
English (en)
Finnish (fi)
Other versions
FI67371B (fi
FI814080L (fi
Inventor
Folke Lars-Erik Arvidsson
Per Arvid Emil Carlsson
Uli Alf Hacksell
John Stephan Mikael Hjorth
Per Lennart Lindberg
John Lars Gunnar Nilsson
Domingo Sanchez
Nils Uno Eimer Svensson
Haokan Vilhelm Wikstroem
Original Assignee
Astra Laekemedel Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Laekemedel Ab filed Critical Astra Laekemedel Ab
Publication of FI814080L publication Critical patent/FI814080L/fi
Priority to FI831681A priority Critical patent/FI831681L/fi
Publication of FI67371B publication Critical patent/FI67371B/fi
Application granted granted Critical
Publication of FI67371C publication Critical patent/FI67371C/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polyamides (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Claims (6)

1. Förfarande för framstä11ning av en farmakologiskt aktiv förening med forme In Y R '-(CH.J 2 n dar n är 1 eller 2, Y är OH, R^OO-, R2R3I\ICCG- eller R40, varvid R^ är en alkylgrupp med 1-5 kolatomer, en fenyl-, 2,6-dimetylfe ny 1- eller 3- eller 4-hydroxifenyIgrupp eller en 3- eller 4 - a 1kanoy1oxife nyIgrupp med formeln 5 2 oär R' är en alkylgrupp med 1-5 kolatomer, R är en alkylgrupp med 1-5 kolatomer, en fenyletyl-, bensyl- eller fenyl" 3 grupp, R är H eller en alkylgrupp med 1-5 kolatomer, Λ F; är en allyl- eller bensylgrupp ooh R är en alkylgrupp med 1-5 kolatomer, en hydroxiai ky 1-, dimetylaminoalky 1-eller mety11ioa1 ky 1grupp med 2-5 kolatomer i alkyldelen ooh med heteroatomen bunden i annan position än 1-ställning eller en annan alkenylgrupp med 3-5 kolatomer än 1-alkenyl, sasom bas eller farmaceutiskt acceptabelt syraadditionssalt därav, kännetecknat av att a) en eter eller ester med formeln Ra0 OrV ct*2Jn se 67371 väri Rö representerar en kolväte- eller acylrest, och n och R är som definierats ovan, spaltas for att bilda en förening enligt formel I där Y är en hydroxigrupp, eller b) i en förening enligt formeln Z *- ( CH., ) ^ n väri Z representerar SO^H, Cl eller och n och R är som definierats ovan, gruppen Z ersättes med en hydroxigrupp tij1 bildning av en förening enligt formel I där Y representerar en hydroxigrupp, eller c) en förening enligt formel I Y | rr (CH^)n väri Y är OH och R är annat an hydroxialkyl och som ytter- ligare definierats ovan, och n är som definierats ovan, omvandlas tili en förening enligt samma formel, väri Y är R^COO- eller R2RJNC00- eller R40, där R1, R2, R3 och R4 är som definierats ovan, genom att behandla den förstnämnda föreningen med en lämplig karboxylsyrahalid R^COX eller -anhydrid (R^C0)_,0 eller med en lämplig karbamoylhalid 2 3 ^ 2 R R NCOX eller isocyanat R NCO, i närvaro av en bas eller 4 syra, eller med en passande allyl- eller bensylhalid R X närvaro av en bas, varvid X betecknar en halogen, eller 99 6 7 3 71 d) en förening enligt formel 6ur *—^H2Jn väri n och Y är som definierats ovan, omvandlas tili en förening enligt formel I genom alkylering av kväveatomen med ett lämpligt alkyleringsmedel, eller e) en amid- eller imidinnehällande förening enligt formeln R^(j) OI /N3 IV C (CH_)—ΓΓ 2 n 1 2 väri M och M är lika eller olika och vardera represen- terar -CH0- eller __C = 0, och M är -C-Ru när bSde M och
2 II 0 n2 är -CH2-/ och i andra fall PV3 Mr R, och Rc är H, en alkylgrupp eller alkoxylgrupp som innehäller 1-4 kolatomer, en hydroxialkyl-, dimetylaminoalkyl- eller metyltioalkyl-grupp som innehäller 1-5 kolatomer eller en alkenylgrupp med 2-4 kolatomer, och R1"* är H, R^CO, allyl eller bensyl, och R och R^ är som definierats ovan, omvandlas tili en förening enligt formeln I där Y är en hydroxi, allyloxi^-eller bensyloxig^riipp,, genom reduktion av amid- eller imid-funktionen och esterfunktionen R^COO om den är närvarande, eller 100 6 7 3 71 f) en förening enligt formeln Y1 JJ VI1 väri Y är bensyloxi eller Y, varvid Y är som definierats ovan emellertid annat än O-allyl, och R är en alkylgrupp som innehäller 1-5 kolatomer eller en hydroxialkyl-, di- metylaminoalkyl- eller metyltioalkylgrupp med 2-6 kolatomer och som har heteroatomen bunden i en annan position än 1- positionen, omvandlas genom reduktion tili motsvarande förening enligt fcrmel I där n är 2, varvid när Y är ben-syloxi en förening enligt formel I där Y är OH erhälles, varefter eventuellt en bas som erhällits omvandlas tili ett farmaceutiskt acceptabelt. syraadditionssalt eller ett er-hället sait omvandlas tili basen eller tili ett annat far-maceutiskt acceptabelt syraadditionssalt, och eventuellt en erhällen isomerisk blandning separeras tili en ren isomer.
FI814080A 1979-12-05 1981-12-18 Foerfarande foer framstaellning av nya farmakologiskt aktiva fenylazacykloalkaner FI67371C (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI831681A FI831681L (fi) 1979-12-05 1983-05-13 Nya foereningar som aer anvaendbara som mellanprodukter vid framstaellning av farmakologiskt aktivafenyl-azacyklo-alkaner

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE7910026 1979-12-05
SE7910026 1979-12-05
SE8000319 1980-12-05
PCT/SE1980/000319 WO1981001552A1 (en) 1979-12-05 1980-12-05 New phenyl-azacycloalkanes

Publications (3)

Publication Number Publication Date
FI814080L FI814080L (fi) 1981-12-18
FI67371B FI67371B (fi) 1984-11-30
FI67371C true FI67371C (fi) 1985-03-11

Family

ID=20339477

Family Applications (1)

Application Number Title Priority Date Filing Date
FI814080A FI67371C (fi) 1979-12-05 1981-12-18 Foerfarande foer framstaellning av nya farmakologiskt aktiva fenylazacykloalkaner

Country Status (17)

Country Link
US (1) US4426386A (sv)
EP (2) EP0030526B1 (sv)
JP (1) JPS6135175B2 (sv)
AT (1) ATE42281T1 (sv)
AU (1) AU542153B2 (sv)
CA (1) CA1147339A (sv)
DD (1) DD155065A5 (sv)
DE (1) DE3070247D1 (sv)
DK (1) DK155793C (sv)
ES (3) ES497489A0 (sv)
FI (1) FI67371C (sv)
GR (1) GR72841B (sv)
HU (1) HU185422B (sv)
IE (1) IE50674B1 (sv)
PT (1) PT72172B (sv)
SE (1) SE8107742L (sv)
WO (1) WO1981001552A1 (sv)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE446335B (sv) * 1982-03-30 1986-09-01 Astra Laekemedel Ab Ren enantiomer av en metasubstituerad 3-fenyl-1-propylpiperidin
US4937346A (en) * 1979-12-05 1990-06-26 Per Arvid Emil Carlsson Phenyl-azacykloalkanes
SE8305362D0 (sv) * 1983-09-30 1983-09-30 Astra Laekemedel Ab Novel substituted phenylazacycloalkanes, processes for preparation and pharmaceutical preparations for such compounds
EP0077607A1 (en) * 1981-09-17 1983-04-27 Beecham Group Plc N-substituted 3-aryl piperidines and derivatives thereof
US4719219A (en) * 1982-03-30 1988-01-12 Per A. E. Carlsson Phenyl-azacycloalkanes and use thereof in treatment of central nervous system disorders
ATE36153T1 (de) * 1982-10-01 1988-08-15 Hoffmann La Roche Spaltung von rac. 1-propyl-3-aryl-piperidinen.
US4593037A (en) * 1984-07-26 1986-06-03 Pfizer Inc. 1,3-disubstituted piperidine compounds as neuroleptic agents
JPH0657695B2 (ja) * 1985-07-12 1994-08-03 エーザイ株式会社 4−シアノピペリジン誘導体
US4826869A (en) * 1988-02-19 1989-05-02 Syntex (U.S.A.) Inc. N-(lower alkyl)-2-(3'ureidobenzyl)pyrrolidines
DE3930282A1 (de) * 1989-09-11 1991-03-21 Boehringer Ingelheim Kg Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit
GB9113031D0 (en) * 1991-06-17 1991-08-07 Smithkline Beecham Plc Compounds
SE9802546D0 (sv) * 1998-07-15 1998-07-15 Ross Nicholas Waters Medicinal product and method for treatment and prevention of dyskinesia
CA2368647A1 (en) * 1999-03-31 2000-10-05 The Procter & Gamble Company Viral treatment
US7346938B2 (en) * 2002-08-02 2008-03-25 Roy W. Mattson, Jr. Retrofit suction sanitation safety cover
EP1707558A1 (en) * 2005-03-21 2006-10-04 Ferrer Internacional, S.A. Benzoic acid ester compounds, compositions, uses and methods related thereto

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2892842A (en) 1959-06-30 Their preparation
CH372667A (de) * 1957-09-26 1963-10-31 Robins Co Inc A H Verfahren zur Herstellung von 3-Aryl-3-pyrrolidinolen
FR1248129A (fr) * 1959-02-12 1960-12-09 Mead Johnson & Co Procédé de préparation des 1-acyl- et 1-carbalkoxy-3 pyrrolidinols
US2975193A (en) * 1959-06-18 1961-03-14 Parke Davis & Co Organic amine compounds and method of obtaining the same
NO116115B (sv) * 1962-06-01 1969-02-03 Parke Davis & Co
DK104736C (da) * 1962-06-20 1966-06-27 Parke Davis & Company A Corp O Fremgangsmåde til fremstilling af optisk aktive eller racemiske pyrrolidin-derivater eller syreadditionssalte deraf.
DK105337C (da) * 1962-06-20 1966-09-19 Parke Davis & Company A Corp O Fremgangsmåde til fremstilling af optisk aktive eller racemiske pyrrolidinforbindelser eller syreadditionssalte deraf.
DK104980C (da) * 1962-06-20 1966-08-01 Parke Davis & Company A Corp O Fremgangsmåde til fremstilling af optisk aktive eller racemiske 1-methylpyrrolidinderivater eller syreadditionssalte deraf.
DE1470155A1 (de) * 1963-04-11 1969-06-04 Parke Davis & Co Neue Pyrrolidinverbindungen,ihre Saeureadditionssalze,sowie Verfahren zu deren Herstellung
GB1012008A (en) * 1963-08-01 1965-12-01 Parke Davis & Co Process for the production of pyrrolidine compounds
GB1198973A (en) 1969-02-07 1970-07-15 Parke Davis & Co Pyrrolidine Compounds with an Unsaturated Substituent and Methods for their Production
US3635982A (en) * 1969-04-08 1972-01-18 American Home Prod Amino-substituted-quinoxalinyloxazolidines and -oxazines
CH526536A (de) 1970-02-05 1972-08-15 Sandoz Ag Verfahren zur Herstellung neuer 3-Phenylpyrrolidinderivate
GB1283452A (en) * 1970-07-24 1972-07-26 Parke Davis & Co Substituted 1,3-dialkylpyrrolidines and processes for their production
US3970656A (en) * 1974-06-11 1976-07-20 Government Of The United States 1-Alkyl-4-m-hydroxyphenyl-4-propionyl piperidines
FR2310762A1 (fr) 1975-05-16 1976-12-10 Roussel Uclaf Nouveaux derives n-substitues de la phenyl piperidine et leurs sels, procede de preparation et application a titre de medicaments
FR2310761A1 (fr) 1975-05-16 1976-12-10 Roussel Uclaf Nouveaux derives de la phenyl-piperidine et leurs sels, procede de preparation et application a titre de medicaments
DE2701705A1 (de) * 1976-01-28 1977-08-04 Sandoz Ag Neue organische verbindungen, ihre verwendung und herstellung
FR2340734A1 (fr) * 1976-02-13 1977-09-09 Roussel Uclaf Nouveaux derives de la m-trifluoromethylphenyl piperidine et leurs sels, procede de preparation et application a titre de medicaments
FR2380261A2 (fr) * 1977-02-11 1978-09-08 Roussel Uclaf Nouveaux derives de la m-trifluoromethylphenylpiperidine et leurs sels, procede de preparation et application a titre de medicaments

Also Published As

Publication number Publication date
SE8107742L (sv) 1981-12-23
ES8205768A1 (es) 1982-08-01
ES8300092A1 (es) 1982-10-01
ATE42281T1 (de) 1989-05-15
WO1981001552A1 (en) 1981-06-11
DK155793C (da) 1989-10-02
JPS56501679A (sv) 1981-11-19
EP0084920B1 (en) 1989-04-19
ES8300703A1 (es) 1982-11-01
ES508030A0 (es) 1982-10-01
EP0030526B1 (en) 1985-02-27
ES497489A0 (es) 1982-08-01
DK342881A (da) 1981-07-31
PT72172B (en) 1982-07-05
AU6642681A (en) 1981-06-19
EP0084920A2 (en) 1983-08-03
FI67371B (fi) 1984-11-30
PT72172A (en) 1981-01-01
DK155793B (da) 1989-05-16
ES508029A0 (es) 1982-11-01
CA1147339A (en) 1983-05-31
IE802545L (en) 1981-06-05
AU542153B2 (en) 1985-02-07
JPS6135175B2 (sv) 1986-08-12
DE3070247D1 (en) 1985-04-04
EP0084920A3 (en) 1985-05-22
US4426386A (en) 1984-01-17
EP0030526A1 (en) 1981-06-17
HU185422B (en) 1985-02-28
GR72841B (sv) 1983-12-07
FI814080L (fi) 1981-12-18
DD155065A5 (de) 1982-05-12
IE50674B1 (en) 1986-06-11

Similar Documents

Publication Publication Date Title
FI67371C (fi) Foerfarande foer framstaellning av nya farmakologiskt aktiva fenylazacykloalkaner
Hacksell et al. 3-Phenylpiperidines. Central dopamine-autoreceptor stimulating activity
FI78067B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 1-alkyl-2-aminotetralinderivat och en vid foerfarandet anvaend mellanprodukt.
US20010051633A1 (en) Subtype-selective NMDA receptor ligands and the use thereof
US20110160223A1 (en) NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders
NO174044B (no) Analogifremgangsmaate for fremstilling av et terapeutisk aktivt amid-derivat
JP7463318B2 (ja) 6員アザヘテロ環を含有するデルタ-オピオイド受容体調節化合物、同化合物を使用する方法、および同化合物を作る方法
HUE028329T2 (en) 2-Phenylethylamino derivatives acting as calcium and / or sodium channel modulators
CA2217197A1 (en) Novel heterocyclic compounds
US8530663B2 (en) 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
EP3582783B1 (en) 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
CN105008345A (zh) 可用作gpr120的激动剂的双环吡咯衍生物
NO803693L (no) 2,3-indoldion-derivater.
CN110372571A (zh) 一种2-(2,2-二芳基乙基)-环胺衍生物或盐及合成和应用与组合物
US4719219A (en) Phenyl-azacycloalkanes and use thereof in treatment of central nervous system disorders
NO142395B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heksahydro-1h-azepiner
CS215038B2 (en) Method of making the hexahydro-1,4-oxazepins
NO138804B (no) Analogifremgangsmaater til fremstilling av aminosyrederivater med antidepressiv virkning
DK162214B (da) Analogifremgangsmaade til fremstilling af en ren enantiomer af 3-fenyl-n-n-propylpiperidinderivater
CN103420898B (zh) 二芳基哌啶类衍生物及其作为多靶点抗抑郁症药物的应用
CA2566937A1 (en) Substituted 2,5-diaminomethyl-1h-pyrroles
US4937346A (en) Phenyl-azacykloalkanes
Herrera Arozamena Melatonin-and resveratrol-based multitarget-directed agents for Alzheimer's disease and photoswitchable muscular nicotinic receptor ligands
CN106905238A (zh) 绿卡色林衍生物、其制法及减肥用途
JPS6022711B2 (ja) トランス−デカハイドロキノリン誘導体,その製造法,及びそれを含む医薬

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: CARLSSON, PER ARVID EMIL